Denali Therapeutics (DNLI) Other Operating Expenses (2024)

Denali Therapeutics' (DNLI) quarterly Other Operating Expenses came in at $14.5 million in Q1 2024.

Denali Therapeutics (DNLI) Other Operating Expenses (2024) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Other Operating Expenses data on file, last reported at $14.5 million in Q1 2024.

On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $14.5 million in Q1 2024; TTM through Dec 2024 was $14.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $14.5 million, changed N/A from the prior year.
Other Operating Expenses for Q1 2024 stood at $14.5 million.
Over the last five years, Other Operating Expenses for DNLI reached as high as $14.5 million in Q1 2024 and fell as low as $14.5 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Denali Therapeutics	4.33 Bn	4.33 Bn	-

Download Data

Date	Value
Mar 31, 2024	14.54 Mn